Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Jolanta
Jolanta Celinska, Colorado Springs, CO US
| Patent application number | Description | Published |
|---|---|---|
| 20100090172 | STABILIZED RESISTIVE SWITCHING MEMORY - A non-volatile resistive switching memory that includes a material which changes between the insulative and conductive states. The material is stabilized against charge trapping by oxygen vacancies by an extrinsic ligand, such as carbon. | 04-15-2010 |
| 20100283028 | NON-VOLATILE RESISTANCE SWITCHING MEMORIES AND METHODS OF MAKING SAME - An integrated circuit memory cell including: a semiconductor having a first active area, a second active area, and a channel between the active areas; and a layer of a variable resistance material (VRM) directly above the channel. In one embodiment, there is a first conductive layer between the VRM and the channel and a second conductive layer directly above the VRM layer. The VRM preferably is a correlated electron material (CEM). The memory cell comprises a FET, such as a JFET or a MESFET. In another embodiment, there is a layer of an insulating material between the VRM and the channel. In this case, the memory cell may include a MOSFET structure. | 11-11-2010 |
Jolanta Chmielowiec, Houston, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20120135051 | GENERATION OF VASCULARIZED HUMAN HEART TISSUE AND USES THEREOF - The present invention relates to the generation of vascularized human heart tissue from human primordial Islet1-positive (ISL1+) progenitors, and more particularly the generation of vascularized human heart tissue from human primordial Islet1+ cardiovascular stem cells which are positive for markers ISL1+/NKX2.5−/KDR−. One aspect of the invention relates to isolation of human ISL1+ primordial cells from human pluripotent cells, such as human ES cells or other human pluripotent stem cell sources, wherein the human ISL1+ primordial cells can differentiate into three different lineages; cardiomyocyte lineages, endothelial lineages and smooth muscle lineages. Another aspect relates to use and implantation of the human primordial ISL1+ progenitors into an animal model to generate human vascularized heart tissue, and more particularly, the production of an in vivo humanized model of vascular disease. One embodiment relates to the use of an in vivo humanized model of vascular disease as an assay, for example to assess drug toxicity and/or identify agents which increase and decrease coronary blood flow to the human vascularized heart tissue. Another embodiment relates to the therapeutic use of human primordial ISL1+ progenitors, for example, in one embodiment the invention provides methods for the treatment cardiovascular disorders and/or congenital heart disease in a subject comprising transplanting into subjects vascularized human heart tissue generated from human ISL1+ progenitors. | 05-31-2012 |
Jolanta Grembecka, Charlottesville, VA US
| Patent application number | Description | Published |
|---|---|---|
| 20110065690 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA - The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions. | 03-17-2011 |
Jolanta Grembecka, Ann Arbor, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20120059003 | INHIBITORS OF INV(16) LEUKEMIA - This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (AML). The inv(16) fusion results in expression of the CBFβ-SMMHC fusion protein in the blood cells of afflicted patients. The present invention provides compounds which inhibit the function of both CBFβ and the CBFβ-SMMHC fusion. These compounds block the growth of an inv(16) leukemia cell line as well as increase its apoptosis, while showing minimal effects against non inv(16) cell lines. As a mechanism to develop inhibitors with selectivity for the CBFβ-SMMHC fusion protein, the present invention further provides dimeric derivatives of these compounds which show both increased potency as well selectivity for CBFβ-SMMHC. These compounds show potent inhibition of an inv(16) leukemia cell line with minimal effects on non inv(16) cell lines. Analysis of the pharmacokinetics of the developed compounds has made it possible to improve the lifetime of the compound in the plasma of mice to a level commensurate with long-term treatment. | 03-08-2012 |
Jolanta Klemberg-Sapieha, Pointe-Claire CA
| Patent application number | Description | Published |
|---|---|---|
| 20100047435 | Hydrogel Attached to Backing and Method for Making Same - The present invention relates to a method of making a preformed hydrogel attach to a polymer backing comprising exposing a surface of the backing to an activated gas and depositing the preformed hydrogel on the exposed surface of the backing, and hydrogel products so formed. This hydrogel product can be used as an active ingredient delivery device, a wound cover and a diagnostic tool. It advantageously replaces hydrogel products using chemicals as adhesive agents. | 02-25-2010 |
Jolanta Polkowska, Essen DE
| Patent application number | Description | Published |
|---|---|---|
| 20120108548 | MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES - This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins. | 05-03-2012 |
Jolanta Pupure, Riga LV
| Patent application number | Description | Published |
|---|---|---|
| 20090137522 | Pharmaceutical Composition on Basis of Reverse Transcriptase Inhibitor and Meldonium - Novel pharmaceutical compositions which contain one of the reverse transcriptase inhibitors, viz., Zidovudine, Lamivudine or Stavudine in clinically efficacious amount and Meldonium as well as pharmaceutically applicable excipients. It has been proved that inclusion of Meldonium in these pharmaceutical compositions essentially diminishes the cardio- and neuro-toxicity of the reverse transcriptase inhibitor. | 05-28-2009 |
Jolanta Solecka, Warszawa PL
| Patent application number | Description | Published |
|---|---|---|
| 20100286196 | NEW INHIBITOR OF DD-PEPTIDASE AND ITS USE AS ANTIBIOTIC OR ANTICANCER DRUG - A new compound is revealed and the strain of | 11-11-2010 |
Jolanta Vidugiriene, Madison, WI US
| Patent application number | Description | Published |
|---|---|---|
| 20110129821 | METHODS FOR CYCLIC NUCLEOTIDE DETERMINATION - The present invention relates in general to cellular analysis tools and more particularly to methods for detecting or determining cyclic nucleotide concentrations in samples. Samples containing cyclic nucleotides may be contacted with a cyclic nucleotide-dependent protein kinase and a detection system which includes a substrate for the cyclic nucleotide-dependent protein kinase. The activities in cyclic nucleotide related pathways may be measured using the detection system. | 06-02-2011 |
Jolanta Vitkute, Vilnius LT
| Patent application number | Description | Published |
|---|---|---|
| 20110207139 | RESTRICTION ENDONUCLEASES AND THEIR APPLICATIONS - Provided is a methylation-specific restriction endonuclease for a DNA duplex substrate, which endonuclease recognizes in a strand of the duplex a 2 to 6 nucleotide recognition sequence comprising a 5-methylcytosine, and cleaves each strand of the duplex at a fixed position outside the recognition sequence. | 08-25-2011 |